Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Explore this paper's citation graph
Summary
Progression‐free survival was significantly longer with avelumab plus axitinib than with sunit inib among patients who received these agents as first‐line treatment for advanced renal‐cell carcinoma.
- Type
- article
- Published
- 2019-02-16
- Cited by
- 2,051
- References
- 34
- Access
- Open access
- OpenAlex
- https://openalex.org/W2911812451
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:73468963
Keywords
Axitinib, Avelumab, Sunitinib, Renal cell carcinoma, Medicine
References
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti‐tumour effect in vivo
- Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.
- Discrete sequential boundaries for clinical trials
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
- Repeated confidence intervals for group sequential clinical trials.
- Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer
- A Comparison of the Renal Cell Carcinoma Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy –Kidney Symptom Index (FKSI)
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma
- Systemic therapy in metastatic renal cell carcinoma
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
Cited by
- Longitudinal bioluminescence imaging to monitor breast tumor growth and treatment response using the chick chorioallantoic membrane model
- NCCN Guidelines Insights: Kidney Cancer, Version 2.2020.
- Targeted therapy for metastatic renal cell carcinoma.
- Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.
- The balancing act between cancer immunity and autoimmunity in response to immunotherapy
- Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
- Axitinib–ICIs boost the RCC armamentarium
- Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score.
- Outcomes of Patients with Metastatic Clear-cell Renal Cell Carcinoma Treated with Second-Line VEGFR-TKI after First-Line Immune Checkpoint Inhibitors
- Status quo: Immuntherapie des klarzelligen Nierenzellkarzinoms
- Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
- Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy
- Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
- Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
- The Intersection between Tumor Angiogenesis and Immune Suppression
- Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
- Immune-based combination therapy for metastatic kidney cancer
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- Towards individualized therapy for metastatic renal cell carcinoma
- Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Related papers
- Axitinib combination therapies versus sunitinib for renal cell carcinoma.
- MP39-20 MOLECULAR MECHANISM UNDERLYING CYTOTOXIC ACTIVITY OF AXITINIB IN SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA ACHN CELLS
- MP35-02 MOLECULAR MECHANISM MEDIATING CYTOTOXIC ACTIVITY OF AXITINIB IN SUNITINIB-RESISTANT HUMAN RENAL CELL CARCINOMA CELLS
- HSR20-096: Budget Impact Analysis of Avelumab Plus Axitinib for the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
- Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells
- A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
- Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
- Effects of Tyrosine Kinase Inhibitors on Blood Pressure in Patients with Unresectable or Advanced Recurrent Renal Cell Carcinoma-Bayes-Mixed Treatment Comparison Meta-Analysis.
- FDA approves avelumab plus axitinib for renal cell carcinoma
- Possibilities of the combination of avelumab and axitinib in the first line in patients with advanced renal cell carcinoma